Figure 5.
Sequence-dependent anti-proliferative effect of combined treatment with Sora and Rsv on (A) Hep3b and (B) HepG2 hepatic cancer cell lines. The cells were treated with a combination of Sora (5 μM) and Rsv (40 or 80 μM) in (a) a sequential, (b) inverted sequential and (c) concomitant manner. Cell growth was monitored by MTT assay. Sora, sorafenib; UT, untreated; Rsv, resveratrol, *P<0.05 (Sora + 40 μM Rsv) vs. Sora, **P<0.05 (Sora + 80 μM Rsv) vs. Sora, ***P<0.05 Sora vs. (Sora + 40 μM Rsv or 80 μM Rsv).
